Nonetheless, most reports of post-transplant ICI use in the treatment of HCC are based on cases where anti PD-1 therapy was used (as it is preferred for HCC), making it difficult to assess if anti-PD-1 therapy (compared to anti-CTLA-4) has a higher risk of rejection, or if the findings are biased towards its higher use[67,86]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.